GO
Loading...

Enter multiple symbols separated by commas

Pfizer Inc

More

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • Biotech investors: These are the key names to know Wednesday, 13 May 2015 | 11:53 AM ET
    Biotech

    Ahead of the world's biggest cancer research conference, the American Society of Clinical Oncology meeting, here are the companies to watch.

  • --Amgen in late 2012 bought Decode Genetics for $415 million in cash to gain access to a database of complete genetic sequences of 2,636 Icelanders. --In January 2014, Regeneron Pharmaceuticals Inc signed a deal with Geisinger Health System in Pennsylvania to sequence DNA from as many as 250,000 volunteers from Geisinger's pool of 3 million patients.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • *Tie-up with Montreal scientists on heart disease genes. LONDON, May 13- AstraZeneca is diving deeper into personalised healthcare with two projects that move the concept beyond cancer into respiratory disorders and heart disease. To redress the balance, AstraZeneca said on Wednesday it had signed two deals, one with Abbott Laboratories for a diagnostic test...

  • Gurpaul Bedi had one for colon cancer that spread to his lungs. About 10 percent of patients with metastatic colon cancer at the University of Texas MD Anderson Cancer Center now get liquid biopsies. "I think it's wonderful," said Bedi, who lives in Atlanta and goes to Houston for his care.

  • US companies hoarding $1 trillion in cash Monday, 11 May 2015 | 2:10 AM ET
    US dollars

    Just five US companies are hoarding nearly half a trillion dollars as the country’s tax code and a tepid global economy deter firms from spending.

  • NEW YORK, May 11- It wasn't long ago that politics, like religious orientation or sexual preference, was a taboo topic in the American workplace. The Washington trade group, which has offices across the street from the White House, helps firms such as Wal-Mart, Halliburton and Lockheed Martin mobilize employees on policy issues important to the companies.

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • Traders work on the floor of the New York Stock Exchange (NYSE)

    U.S. stocks closed lower, reversing a positive open, as investors weighed higher yields and energy prices ahead of Friday's important jobs report.

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • May 5- Animal health products maker Zoetis Inc said it plans to cut up to a quarter of its workforce and exit nearly 40 percent of its manufacturing plants in its first major restructuring since being spun off from Pfizer Inc two years ago. The restructuring comes a month after activist investor Pershing Square seated their second nominee on Zoetis's board in...

  • A campus brain drain in the US no one talks about Tuesday, 5 May 2015 | 11:00 AM ET
    Immigration reform protesters march to the White House last August.

    Immigration policy discards some of the brightest college grads because they are foreigners, and it's costing our entrepreneurial economy.

  • May 5- Animal health products maker Zoetis Inc said it would reduce operations in Venezuela and consider selling or exiting 10 manufacturing sites over the long term. Ackman's Pershing Square Capital Management was Zoetis's biggest shareholder with an 8.35 percent stake as of April 10, according to Thomson Reuters data. Zoetis, which was spun off from Pfizer...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks traded lower as investors weighed a weaker-than-expected GDP report and earnings reports ahead of the Fed statement release.

  • Dust off the weak economy trade: 5 buys Wednesday, 29 Apr 2015 | 12:23 PM ET
    Traders work the floor of the New York Stock Exchange.

    U.S. GDP figures stalled last quarter, setting up a winning short-term trade in certain sectors and slices of the stock market.